BioCentury | Oct 3, 2019
Product Development

Kidney is the new liver: why kidney indications are coming into sharp focus

Interest in kidney diseases is mounting among investors, biotechs and pharmas at a rate reminiscent of the liver disease explosion almost a decade ago. The momentum is driven by improvements at both ends of the...
BioCentury | Aug 22, 2016
Clinical News

Lucassin terlipressin: Phase III started

...Lebanon, N.J. Mallinckrodt plc (NYSE:MNK), St. Louis, Mo. Product: Lucassin terlipressin Business: Hepatic Molecular target: Vasopressin 1 (V1) receptor...
BioCentury | Dec 6, 2010
Clinical News

Lucassin terlipressin: Phase III started

...Chester, U.K. Orphan Therapeutics LLC , Lebanon, N.J. Product: Lucassin terlipressin Business: Hepatic Molecular target: Vasopressin 1 (V1) receptor...
BioCentury | Jul 1, 2010
Targets & Mechanisms

PKD: cease and de-cyst

Marketed treatments for polycystic kidney disease manage symptoms but do not slow disease progression. A research team led by Genzyme Corp. now has shown that blocking biosynthesis of the glycosphingolipid glucosylceramide could help treat the...
BioCentury | Oct 12, 2009
Clinical News

VA111913: Phase I data

...Vantia Therapeutics Ltd. , Southampton, U.K. Product: VA111913 (formerly VT913 ) Business: Endocrine Molecular target: Vasopressin 1 (V1) receptor...
BioCentury | Oct 12, 2009
Clinical News

VA111913: Phase II started

...Vantia Therapeutics Ltd. , Southampton, U.K. Product: VA111913 (formerly VT913 ) Business: Endocrine Molecular target: Vasopressin 1 (V1) receptor...
BioCentury | Mar 30, 2009
Clinical News

VA111913: Completed Phase I enrollment

...Therapeutics Ltd. , South Hampton, U.K. Product: VA111913 (formerly VT913 ) Business: Endocrine Molecular target: Vasopressin 1 (V1) receptor...
BioCentury | Aug 4, 2008
Clinical News

SSR149415: Development discontinued

...for the discontinuation. sanofi-aventis Group (Euronext:SAN; NYSE:SNY), Paris, France Product: SSR149415 Business: Neurology Molecular target: Vasopressin 1 (V1) receptor...
BioCentury | Sep 24, 2007
Clinical News

Vaprisol conivaptan: Phase III data

...20, 2004). Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Product: Vaprisol conivaptan Business: Renal Molecular target: Vasopressin 1 (V1) receptor...
BioCentury | Aug 7, 2006
Clinical News

Terlipressin: Phase III data

...in the U.S. Orphan Therapeutics LLC , Lebanon, N.J. Product: Terlipressin Business: Hepatic Molecular target: Vasopressin V1 receptor...
Items per page:
1 - 10 of 14